Reina Salazar, MD
Allergy & Immunology · Saint Clair Shores, MINPI 1962588681
Payments from drug & device makers
Across 799 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- GSK$2K
- Sanofi$2K
- CSL Behring$2K
- Amgen$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $5K from 29 others
What the payments were for
- Consulting fees$1791%
- Food & beverage$18,08198%
- Education$2802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 171 | $4,946 |
| GSK | 120 | $2,289 |
| Sanofi | 66 | $1,712 |
| CSL Behring | 74 | $1,685 |
| Amgen | 78 | $1,445 |
| Regeneron Healthcare Solutions, Inc. | 52 | $1,250 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $750 |
| Pfizer | 26 | $495 |
| Novartis | 22 | $456 |
| Alk-abello, Inc | 15 | $392 |
| Pharming Healthcare, Inc. | 11 | $380 |
| Genentech USA, Inc. | 16 | $373 |
| Kaleo, Inc. | 16 | $315 |
| ADMA Biomanufacturing LLC | 20 | $305 |
| Bio Products Laboratory USA, Inc. | 14 | $251 |
| Boehringer Ingelheim | 10 | $214 |
| Grifols USA, LLC | 7 | $151 |
| Organon | 2 | $137 |
| Sanofi-aventis U.S. LLC | 3 | $122 |
| Biocryst US Sales Co., LLC | 5 | $119 |
| Teva Pharmaceuticals USA, Inc. | 6 | $113 |
| Aimmune Therapeutics, Inc. | 5 | $112 |
| Octapharma USA, Inc. | 5 | $111 |
| Optinose US, Inc. | 5 | $100 |
| LEO Pharma Inc. | 3 | $57 |
| Phadia US Inc. | 3 | $56 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $51 |
| Ionis Pharmaceuticals, Inc. | 1 | $36 |
| Paratek Pharmaceuticals, Inc. | 1 | $26 |
| Blueprint Medicines Corporation | 1 | $18 |
| Merck | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $16 |
| Dermavant Sciences, Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,539 in reported general payments places this provider in the 75th percentile of 119 allergy & immunology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $47,189 |
| Dupixent SyringeDupilumab | 12 | $45,538 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $15,478 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 56 | $11,321 |
| DuleraMometasone/Formoterol | 14 | $7,667 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,248 |
| Pulmicort FlexhalerBudesonide | 13 | $6,014 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $5,344 |
| Serevent DiskusSalmeterol Xinafoate | 13 | $5,240 |
| Qvar RedihalerBeclomethasone Dipropionate | 20 | $4,981 |
| Wixela InhubFluticasone Propion/Salmeterol | 30 | $4,504 |
| Arnuity ElliptaFluticasone Furoate | 13 | $4,036 |
| Ventolin HfaAlbuterol Sulfate | 48 | $3,702 |
| Montelukast Sodium | 164 | $3,452 |
| Epinephrine | 16 | $3,404 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $2,289 | $58,47364 claims |
| AstraZenecaPulmicort Flexhaler, Symbicort | $4,946 | $11,35835 claims |
| MerckDulera | $17 | $7,66714 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $113 | $4,98120 claims |
| Hikma Pharmaceuticals USAEpinephrine | $14 | $3,40416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 119 allergy & immunology providers in Michigan.
Other allergy & immunology in Saint Clair Shores
- Anne WhiteSaint Clair Shores$10K
- Jeffrey LefleinYpsilanti$7.9M
- Cem AkinNorthville$3M
- Alan BaptistAnn Arbor$2.5M
- Suresh AnneFlint$1.1M
- Steven StrykCanton$949K
- Hassan NasirWest Branch$736K
- Theodore KelbelGrand Rapids$695K
- Rajan RavikumarBrighton$661K
- Georgiana SandersAnn Arbor$607K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.